skip to main content
UK Health Security Agency

htr-9c

htr-9c

Catalogue No.

10080902

Cell Line Name

htr-9c

Cell Line Description

Mouse monoclonal against human CD-120a. TNF receptor p55 prepared from HL-60 cells (htr-mAb series). Application: FACS, Sandwich ELISA for soluble p55 TNF-R.

Characteristics

Myeloma

PAI

Immunogen

Human CD120a (TNF receptor p55)

Immunological Donor

Mouse spleen

Antibody Isotype

IgG1

Morphology

Spherical

Tissue of Origin

Hybrid

Culture Conditions

Cell Type

Hybridoma

Subculture Routine

Seed cultures between 1-3 x 10⁵ cells/ml; Saturation density 8-10 x 10⁵ 5% CO₂; 37°C. When recovering hybridoma cultures from frozen it is not unusual for growth to be slower than expected initially and there may be an observed decrease in viability. Establishment of an actively proliferating culture may take up to 2 weeks. On resuscitation a centrifugation step to remove the cryoprotectant is essential. Rapidly thaw the frozen ampoule in a water bath at 37°C for 1-2 minutes. Transfer the contents to a centrifuge tube and slowly add 5-10ml of prewarmed growth media+. Remove a sample for counting. Centrifuge at 100 x g for 2-3 minutes to pellet cells and seed at a relatively high density of 5-7 x 10µ cells/ml. Place culture flask flat and observe regularly until viable proliferating cells are seen. Often hybridoma cultures may benefit from being resuspended with media supplemented with 20% FBS in the early critical stage of culture establishment immediately post resuscitation. Once the culture is established in culture the FBS can be reduced to 10%.

Culture Medium

Iscoves Modified Dulbeccos Medium (IMDM) + 2mM glutamine + 25 U/ml Interleukin-6 (IL-6) + 5-10% Foetal Bovine Serum (FBS). Where the cells are grown under static conditions, 0.02% EDTA maybe required to dislodge them from the plastic.

Growth Mode

Suspension

Additional Info

Depositor

Dr Claudia Bardouille, F.Hoffmann-La Roche Ltd, Pharmaceuticals Division, Discovery Technology, Building 62/R.212, CH-4070 Basel, Switzerland. Originator: Dr Manfred Brockhaus, F.Hoffmann-La Roche Ltd, CH-4070 Basel, Switzerland.

Country of Origin

Switzerland

Hazard Group (ACDP)

2

References

References

Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. (1990) Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A. 87(8):3127-31 PMID: 2158104.

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: htr-9c (ECACC 10080902)

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.